|
 Two doses of the drug, tofacitinib, maintained the
treatment effect in patients suffering from moderate-to-severe
chronic plaque psoriasis, the company said.
The trial data showed that patients who stayed on the drug
maintained the treatment effect and, among those who stopped
therapy, some patients were able to regain the original treatment
effect when given tofacitinib, Pfizer said.
(Reporting by Esha Dey in Bangalore; Editing by Savio D'Souza)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
 |
